Global Beta Blocking Medicine Sales by Country

In 2023, Croatia led beta blocker sales globally with $208.3 million, followed by Canada and South Korea. Canada experienced a sales decline, whereas South Korea, Spain, and Chile showed positive growth. Sweden, Slovakia, and Denmark saw modest increases, while Finland and Costa Rica faced declines. Iceland achieved the highest growth rate. Over the past five years, the compound annual growth rate indicates a modest global average increase in beta blocker sales.

Future trends to watch include:

  • Potential market expansions in Asia due to increasing healthcare spending.
  • Innovations in drug delivery and personalized medicine boosting sales.
  • The impact of global health policies on drug pricing and accessibility.

Top countries in Beta Blocking Medicine Sales by Country

# 10 Countries Million US Dollars PPP Last Year YoY 5-years CAGR
1 1 Croatia 208.3 2023 -1.93% +0.34% View data
2 2 Canada 201.4 2023 -2.42% -4.11% View data
3 3 South Korea 182.7 2023 +1.39% +3.38% View data
4 4 Spain 179.7 2023 +2.16% +4.14% View data
5 5 Chile 59.9 2023 +2.22% +4.62% View data
6 6 Sweden 52.2 2023 -0.38% +1.95% View data
7 7 Slovakia 48.8 2023 +2.52% +2.95% View data
8 8 Denmark 21.6 2023 +0.47% +3.04% View data
9 9 Finland 21.1 2023 -2.76% -3.64% View data
10 10 Norway 20.9 2023 -0.48% +1.5% View data

Top Countries about Beta-Blocker